Table 2.
Predictive performance of the infliximab population pharmacokinetic model in an external cohort of children with Crohn's disease.
| Predictions using Clinical Characteristicsa Only | Predictions using Clinical Characteristicsa & IFX Concentrations | |
|---|---|---|
| Prediction errorb (μg/mL) | ||
|
| ||
| Median | -0.57 | -0.15 |
| 95% confidence interval | -1.4 to -0.03 | -0.37 to -0.05 |
|
| ||
| Percentage prediction error (%) | ||
|
| ||
| Median (%) | -13.6% | -5.6% |
| 95% confidence interval | -34.5 to -0.8% | -8.7 to -2.3% |
|
| ||
| Absolute prediction errorc (μg/mL) | ||
|
| ||
| Median | 1.3 | 0.26 |
| 95% confidence interval | 1.0 to 1.8 | 0.15 to 0.40 |
|
| ||
| Absolute percentage prediction error (%) | ||
|
| ||
| Median | 49.3% | 10.7% |
| 95% confidence interval | 41.4 to 59.7% | 7.4 to 13.3% |
IFX, Infliximab
a
Clinical characteristics that predicted infliximab pharmacokinetics in the model were weight, serum albumin, concomitant immunomodulation therapy, and presence of antibodies to infliximab.
b
Prediction error is a measure of bias of the pharmacokinetic model.
c
Absolute prediction error is a measure of precision of the pharmacokinetic model.